Bio News

Swiss pharmaceutical company Roche has signed an agreement with U.S.-based Atavistik Bio to develop treatments for cardiovascular, renal and metabolic diseases.
Roche will pay Atavistik Bio $70 million (about 93.8 billion won) upfront.
Atavistik Bio will handle candidate discovery and research, after which Roche will continue preclinical development.

Biobook Team
biobookmedia@biobook.co.krRoche’s New Drug for Uveitic Macular Edema Faces FDA Decision in July 2027
BMS Reports Concurrent Phase 3 Success in Idiopathic Pulmonary Fibrosis and Solid Tumors
Merck’s $1.3 trillion eye disease drug raises safety and efficacy concerns: “Limited competitiveness”
CHA Biotech Holds 24.23% Stake in CMG Pharmaceutical as Share Consolidation Reduces Its Share Count
Rural Development Administration Develops Two Molecular Markers to Identify Leaf Splitting in Squash
MFDS Begins Distribution of Internationally Certified Reference Materials, Including 24 New Items, for a Total of 882